2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis
2000
Atovaquone and Azithromycin for the Treatment of Babesiosis
Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Atovaquone and Azithromycin for the Treatment of Babesiosis. New England Journal Of Medicine 2000, 343: 1454-1458. PMID: 11078770, DOI: 10.1056/nejm200011163432004.Peer-Reviewed Original ResearchConceptsCommon adverse effectsTreatment of babesiosisAdverse reactionsAdverse effectsCourse of clindamycinRegimen of clindamycinStart of therapyMalaria-like illnessPromising alternative treatmentStandard treatmentAlternative treatmentRegimenClindamycinAzithromycinAtovaquoneMonthsDiarrheaTreatmentBabesiosisQuinineSymptomsSubjectsPercentDaysBabesia microti DNA